Please read and agree to the
terms and conditions
of this site.
I agree
Stream
/tech
Clear filters and search
Format
photo
Tags
biotech
2
×
life sciences
merck
2
×
national blog main
raleigh-durham blog main
2
×
adaptimmune therapeutics
alzheimer's disease
american society of clinical oncology
american urological association
astellas pharma
axel hoos
axovant sciences
belantamab mafodotin
boston blog main
cancer immunotherapy
clinical trials
dostarlimab
europe blog main
europe top stories
fda
glaxosmithkline
lewy body dementia
lyell immunopharma
mirabegron
national
new york blog main
niraparib (zejula)
non-small cell lung cancer
novartis
overactive bladder
parp inhibitor
pembrolizumab keytruda
philadelphia blog main
philadelphia top stories
roivant sciences
san diego
san diego blog main
san diego top stories
synthetic lethality
tesaro
What
approved
2
×
advantages
astellas
bladder
can’t
company
compared
drug
drugs
experimental
fda
generic
glaxosmithkline
glaxosmithkline's
goals
growth
hits
keeps
key
line
long
marketed
mid
new
offer
oncology
outpace
overactive
plans
resurgence
rival
sciences
test
track
treatment
urovant
won
years
Language
unset
Current search:
approved
×
biotech
×
merck
×
" raleigh-durham blog main "
×
{{ ::tile.facetWhoCard }}
{{ ::tile.pubDate | moment: 'fromNow'}}
Paste
[[item:{{::tile.id}}]]
to render this photo inside an other item's description.
PROCESSING
TRANSCODING
ERROR
EXTRACTING
ERROR
{{::tile.title}}